MATRix/IELSG43: high-dose chemotherapy and autologous stem cell transplant versus non-myeloablative consolidation in primary CNS lymphoma
In the largest trial ever run in lymphoma of the brain, a stem cell transplant after MATRix chemotherapy kept 78 percent of patients free of progression at three years against 51 percent with conventional consolidation chemotherapy, and lengthened survival.
Overview
Randomised phase 3 trial in 368 patients aged 18 to 70 with newly diagnosed primary CNS lymphoma: after four cycles of MATRix, 230 patients with responding or stable disease were randomised to high-dose carmustine and thiotepa with autologous stem cell transplant or two cycles of R-DeVIC; 229 were analysed.
At a median follow-up of 45.3 months three-year progression-free survival was 78 percent after transplant against 51 percent after R-DeVIC (hazard ratio 0.43, p 0.0003), and overall survival was also improved. Adverse events per patient were 14.6 against 9.3; fatal serious adverse events after consolidation occurred in five transplant patients (infections, pulmonary embolism) and two R-DeVIC patients (acute myeloid leukaemia).
- Three-year progression-free survival 78 percent (95% CI 69 to 85) with transplant versus 51 percent (41 to 60) with R-DeVIC; hazard ratio 0.43 (0.27 to 0.68), p 0.0003.
- Overall survival significantly improved with transplant.
- Mean adverse events per patient 14.6 versus 9.3; five versus two fatal serious adverse events after consolidation.
High-dose chemotherapy with autologous transplant is the preferred consolidation for fit patients with primary CNS lymphoma who complete MATRix induction.
- Only patients up to 70 who responded to induction and were fit for transplant were randomised; a third of enrolled patients never reached randomisation.
- Transplant carried more toxicity, including fatal infections.
Similar pages
not linked directly; found by shared links- Key paperIELSG32 second randomisation: whole-brain radiotherapy or autologous stem cell transplant as consolidation in primary CNS lymphoma
Shares Carmustine, Thiotepa, Primary CNS lymphoma.
- TrialIELSG32
Shares Carmustine, Thiotepa, Primary CNS lymphoma.
- Key paperIELSG32 first randomisation: the MATRix regimen (methotrexate, cytarabine, thiotepa, rituximab) in primary CNS lymphoma
Shares Thiotepa, Primary CNS lymphoma.
- TechnologyAutologous stem cell transplant (high-dose therapy)
Shares Carmustine, MATRix/IELSG43, Thiotepa, Primary CNS lymphoma.